These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21879295)

  • 21. Positron emission tomography as an imaging biomarker.
    Weber WA
    J Clin Oncol; 2006 Jul; 24(20):3282-92. PubMed ID: 16829652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small animal PET in preclinical studies: opportunities and challenges.
    Riemann B; Schäfers KP; Schober O; Schäfers M
    Q J Nucl Med Mol Imaging; 2008 Sep; 52(3):215-21. PubMed ID: 18551093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging Responses to Immunotherapy with Novel PET Tracers.
    Niemeijer AL; Hoekstra OS; Smit EF; de Langen AJ
    J Nucl Med; 2020 May; 61(5):641-642. PubMed ID: 32086241
    [No Abstract]   [Full Text] [Related]  

  • 24. New PET tracers for evaluation of solid tumor response to therapy.
    Larson SM; Schoder H
    Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):158-66. PubMed ID: 19293764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beyond 18F-fluorodeoxyglucose: making the next generation of PET radiotracers available for oncology research in the UK.
    Gilbert FJ; Fleming IN; Marsden PK
    Nucl Med Commun; 2011 Jan; 32(1):1-3. PubMed ID: 21119502
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts.
    Tsuji AB; Sogawa C; Sugyo A; Sudo H; Toyohara J; Koizumi M; Abe M; Hino O; Harada YN; Furukawa T; Suzuki K; Saga T
    Nucl Med Biol; 2009 May; 36(4):379-88. PubMed ID: 19423005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional PET imaging in cancer drug development.
    Avril N; Propper D
    Future Oncol; 2007 Apr; 3(2):215-28. PubMed ID: 17381421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small-animal PET: a promising, non-invasive tool in pre-clinical research.
    Schnöckel U; Hermann S; Stegger L; Law M; Kuhlmann M; Schober O; Schäfers K; Schäfers M
    Eur J Pharm Biopharm; 2010 Jan; 74(1):50-4. PubMed ID: 19482080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How to Modulate Tumor Hypoxia for Preclinical In Vivo Imaging Research.
    De Bruycker S; Vangestel C; Staelens S; Van den Wyngaert T; Stroobants S
    Contrast Media Mol Imaging; 2018; 2018():4608186. PubMed ID: 30420794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical molecular imaging with positron emission tomography.
    Saleem A; Charnley N; Price P
    Eur J Cancer; 2006 Aug; 42(12):1720-7. PubMed ID: 16797972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neural nAChRs PET imaging probes.
    Mo YX; Yin YF; Li YM
    Nucl Med Commun; 2014 Feb; 35(2):135-43. PubMed ID: 24240192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-clinical evaluation of a 3-nitro-1,2,4-triazole analogue of [18F]FMISO as hypoxia-selective tracer for PET.
    Bejot R; Kersemans V; Kelly C; Carroll L; King RC; Gouverneur V; Elizarov AM; Ball C; Zhang J; Miraghaie R; Kolb HC; Smart S; Hill S
    Nucl Med Biol; 2010 Jul; 37(5):565-75. PubMed ID: 20610161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hybrid imaging by SPECT/CT and PET/CT: proven outcomes in cancer imaging.
    Bockisch A; Freudenberg LS; Schmidt D; Kuwert T
    Semin Nucl Med; 2009 Jul; 39(4):276-89. PubMed ID: 19497404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a Widely Usable Amino Acid Tracer: ⁷⁶Br-α-Methyl-Phenylalanine for Tumor PET Imaging.
    Hanaoka H; Ohshima Y; Suzuki Y; Yamaguchi A; Watanabe S; Uehara T; Nagamori S; Kanai Y; Ishioka NS; Tsushima Y; Endo K; Arano Y
    J Nucl Med; 2015 May; 56(5):791-7. PubMed ID: 25814518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Imaging Insights into Neurodegeneration: Focus on Tau PET Radiotracers.
    Shah M; Catafau AM
    J Nucl Med; 2014 Jun; 55(6):871-4. PubMed ID: 24833492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands.
    Mercier J; Archen L; Bollu V; Carré S; Evrard Y; Jnoff E; Kenda B; Lallemand B; Michel P; Montel F; Moureau F; Price N; Quesnel Y; Sauvage X; Valade A; Provins L
    ChemMedChem; 2014 Apr; 9(4):693-8. PubMed ID: 24446373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Positron emission tomography imaging of small animals in anticancer drug development.
    Aboagye EO
    Mol Imaging Biol; 2005; 7(1):53-8. PubMed ID: 15912276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical studies of SPECT and PET tracers for NET.
    Brom M; Boerman O; Gotthardt M; Oyen WJ
    PET Clin; 2014 Jan; 9(1):63-9. PubMed ID: 25029935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immuno-PET: a navigator in monoclonal antibody development and applications.
    van Dongen GA; Visser GW; Lub-de Hooge MN; de Vries EG; Perk LR
    Oncologist; 2007 Dec; 12(12):1379-89. PubMed ID: 18165614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Critical parameters in targeted drug development: the pharmacological audit trail.
    Banerji U; Workman P
    Semin Oncol; 2016 Aug; 43(4):436-45. PubMed ID: 27663475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.